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http://www.biomedcentral.com/1471-244X/14/349RESEARCH ARTICLE Open AccessThe effects of escitalopram on myocardial
apoptosis and the expression of Bax and Bcl-2
during myocardial ischemia/reperfusion in a
model of rats with depression
Yiming Wang1*†, Hongming Zhang2†, Fangxian Chai1, Xingde Liu3* and Michael Berk4,5,6,7,8Abstract
Background: Major depressive disorder (MDD) is an independent risk factor for coronary heart disease (CHD), and
influences the occurrence and prognosis of cardiovascular events. Although there is evidence that antidepressants
may be cardioprotective after acute myocardial infarction (AMI) comorbid with MDD, the operative
pathophysiological mechanisms remain unclear. Our aim was therefore to explore the molecular mechanisms of
escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 in a rat model of depression during
myocardial ischemia/reperfusion (I/R).
Methods: Rats were divided randomly into 3 groups (n = 8): D group (depression), DI/R group (depression with
myocardial I/R) and escitalopram + DI/R group. The rats in all three groups underwent the same chronic mild stress
and separation for 21 days, at the same time, in the escitalopram + DI/R group, rats were administered
escitalopram by gavage (10 mg/kg/day). Ligation of the rat’s left anterior descending branch was done in the
myocardial I/R model. Following which behavioral tests were done. The size of the myocardial infarction was
detected using 1.5% TTC dye. The Tunel method was used to detect apoptotic myocardial cells, and both the
Rt-PCR method and immunohistochemical techniques were used to detect the expression of Bcl–2 and Bax.
Results: Compared with the D and DI/R groups, rats in Escitalopram + DI/R group showed significantly increased
movements and sucrose consumption (P < .01). Compared with the DI/R group, the myocardial infarct size in the
escitalopram + DI/R group was significantly decreased (P < .01). Compared with the D group, there were
significantly increased apoptotic myocardial cells in the DI/R and escitalopram + DI/R groups (P < .01); however
compared with the DI/R group, apoptotic myocardial cell numbers in the escitalopram + DI/R group were
significantly decreased (P < .01). Compared with the DI/R group, there was a down-regulated Bax:Bcl-2 ratio in the
escitalopram + DI/R group (P < .01).
Conclusions: These results suggest that in patients with AMI comorbid with MDD, there is an increase in
pro-apoptotic pathways that is reversed by escitalopram. This suggests that clinically escitalopram may have a direct
cardioprotective after acute myocardial infarction.
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Cardiovascular disease is a major driver of mortality glo-
bally, and depression a major driver of morbidity. Coron-
ary heart disease (CHD) is the most common type of
cardiovascular disease, and acute myocardial ischemia
(AMI) is the classically emergent expression of CHD with
an attendant mortality risk. With the development of an
increasing understanding of the biology-psychology-social
medicine nexus, there is deeper understanding of the risk
factors of CHD. There is a relationship between social and
psychological factors with CHD and cardiac events, such
that high incident rates of depression and anxiety have
been found in CHD patients [1], and depression has been
proved to be an independent risk factor for CHD, influen-
cing the occurrence and prognosis of cardiovascular
events [2]. The mortality rate in patients with CHD and
depression is higher than that in patients with CHD only
[3]. Our original study [4] suggested that active pro-
apoptotic pathways might be involved in the nexus be-
tween myocardial infarction and depression. It is unclear
whether antidepressant therapy should be included in the
management of AMI patients complicated by depression.
It is of clinical and theoretical importance to have effective
preventive and treatment strategies for depressive patients
complicated by AMI. This has the potential to both im-
prove the survival rates of AMI patients and reduce the
consumption of limited medical resources.
Currently emergency percutaneous coronary interven-
tion (PCI) has become a routine clinical treatment for
AMI, but patients receiving PCI treatment risk post-
operative damage such as myocardial ischemia and re-
perfusion [5]. Although there are some data on the use
of antidepressants in myocardial infarction (MI) comor-
bid with major depressive disorder [6], the pathophysio-
logical processes are unclear. Escitalopram is a widely
used antidepressant, but its effectiveness in AMI patients
complicated with depression awaits further studies. Our
aim was to explore the molecular mechanisms of escitalo-
pram on myocardial apoptosis during myocardial ische-
mia/reperfusion in a rat model of depression, specifically
the expression of Bax and Bcl-2. It was hoped this might
illuminate mechanisms and treatment for AMI patients
complicated by depression.
Methods
Subjects
Male Sprague-Dawley rats (n = 24, weighing 250 g ±
20 g) were used for the experimental procedures).
Twenty-four SD rats were divided randomly into 3 groups,
with 8 rats in each group; D group (depression group), DI/
R group (depression with myocardial ischemia/reperfu-
sion) and escitalopram +DI/R group (escitalopram + de-
pression with myocardial ischemia/reperfusion). The rats
in all three groups underwent the same chronic mildunpredictable stress and separation for 21 days following
which open field and sucrose preference behavioral tests
were conducted. At the same time, for the escitalopram +
DI/R group, distilled water with escitalopram (10 mg/kg/
day) was administered once a day by gavage for 21 days,
while the rats with depression were receiving I/R surgery.
Five rats died during the IR procedure because of arrhyth-
mias, these rats were excluded in the experiments. Ani-
mals were managed in accordance with the American
Psychological Association (APA) ethical standards regard-
ing the treatment of rats and the National Institute of
Health and Guide for the Care and Use of Laboratory
Animals (NIH Publications No. 80-23) revised in 1996,
and the study was approved by the ethics Committee on
the Guidelines for Animal Experiment at Guiyang Medical
University, No: SCXK 2008-0001, provided by Guiyang
Medial University Experimental Animals Center. Efforts
were made to minimize the number of animals used and
their suffering.
Chronic mild stress model (depression)
In this study, the chronic mild unpredictable stress and
separation model was used as a validated animal model
of depression [7]. All rats were given the following
stressors [8,9], consisting each week of repeated periods
of confinement to a small (38 × 20 × 16 cm) cage, re-
straint (1 h), water deprivation (24 h), food deprivation
(24 h), isolation (24 h), flashing light (3 h), forced cold
water swimming (10 minutes) and were group-housed in
a soiled cage overnight. Stressors were used daily in a
random and unpredictable order for 21 days. Open-field
test [10] and sugar water consumption experiments [11]
were carried out 1 day before and 22 days after chronic
mild unpredictable stress and separation to observe the
behavior and anhedonic-like state of all rats.
Open field test and sucrose consumption test
The behavior and anhedonic-like state of all rats were
detected by the open field [10] and sucrose consumption
tests [11]. The behavioral response to a new environ-
ment has been used as an indicator of emotional state.
This includes assessment of horizontal movements (the
total number of crossing squares) and vertical move-
ments (grooming and rearing) during a five-minute
period. A special white square was used (80 × 80 ×
40 cm), which has 25 sectors with black stripes on the
ground. Animals were put separately in the same central
sector, and their activity was recorded during a five-
minute period by an installed video camera. Observers
analyzed the results of videotapes. Sucrose consumption
is a rat model of an anhedonialike state [12]. Every cage
was offered a bottle of water and a bottle of 1% sucrose
water. Total sucrose consumption was measured after
60 minutes.
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In this study, we used the myocardial infarction model
described by Wu et al., which is a validated animal
model of myocardial infarction [13]. The rats were
placed on the operation table face-up after being anes-
thetized by abdominal injection of 10% chloral hydrate
(3 ml/kg), connected with a small animal ventilator and
manual ventilation was conducted at 50-60 times per
minute and tidal volume 2 ml/100 mg. A thoracic inci-
sion of about 2.0 cm was made, and the base of the heart
was exposed by retractors in the central region of the rib
cage. The myocardial infarction model was induced by li-
gating the left anterior descending coronary artery 2 mm
from the tip of the left auricle by polypropylene suture for
40 minutes. Rats were monitored by ECG (electrocardio-
gram) before and after coronary artery ligation. Ischemia
was confirmed by ST-T segment elevation seen in ECG re-
cordings performed on the rats [14]. After the myocardial
surface became blanched, the animal was returned to its
home cage. All rats were administered an analgesic (2 mg/
kg) butorphanol tartrate, s.c. every 8 h during the 24 h
after surgery and an antibiotic (10,000 IU penicillin G, i.
m). Five rats died during the IR procedure because of ar-
rhythmias, these rats were excluded in the experiments.Myocardial infarct size
Twenty-four hours after completion of the behavioral tests
[4], the rats were sacrificed by decapitation. The heart was
removed, the aorta was cannulated and washed with sa-
line, the left anterior descending coronary artery was li-
gated again at the same site, and the aorta was infused
with 2 ml of 0.5% Evan’s blue to determine the extent of
the non-colored ischemic risk area. The myocardium was
then bisected into two parts from the apex to the base
along the left anterior descending coronary artery, which
was frozen at -80°C for five minutes, and then sliced into
2 mm transverse sections and stained using 2,3,5-triphenyl
tetrazolium chloride (1.5%TTC) and myocardial infarction
size (×2) was thus confirmed [15].Preparation of tissue sample
At the end of the experiment, the rats were sacrificed
with abdominal anesthesia and the hearts were har-
vested, cleansed with DEPC water, an adequate propor-
tion of the tissue were obtained and kept in Trozil liquid
tank awaiting RT-PCR testing. The hearts were then put
in 4% paraform solution and fixed at 4°C for 6 hours.
The hearts were cleansed again with 0.01 M PBS, dehy-
drated with ascending series of ethanol, cleared in xy-
lene, embedded in paraffin, sliced continuously at 5 μm,
awaiting myocardial cell apoptosis and immunohisto-
chemistry testing.Myocardial cell apoptosis assay
Tunel apoptosis assay was carried out on myocardial
cells, strictly following the kit instructions. Brown parti-
cles in the cell karyon were indicative of positive cells.
Observation of apoptosis with light microscopy × 400
was performed and 10 sites were chosen. The apoptosis
percentage out of the total number of myocardial cells
was used as the Apoptotic index (AI).
Quantitative measure of Bcl-2 and Bax protein by
immunohistochemical staining
For Bax and Bcl-2 protein determination [16], immuno-
histochemical staining kits for Bax, Bcl-2 were provided
by Wuhan Boster Bioengineering Co., Ltd. (Wuhan,
China). The sections (thickness of 4 μm) were de-waxed
and rehydrated with freshly distilled water. At room
temperature, samples underwent inactivation of endogen-
ous peroxidase for 10 minutes and were then washed with
distilled water for 2 minutes (three times), then immersed
in 0.1 mol/L citrate buffer solution (pH= 6.0) and heated
in a microwave oven until boiling (twice, with a 5-minute
interval). After refrigerated flushing three times with phos-
phate buffered saline (PBS) for 2 minutes, antigen-retrieval
buffers were added for 10 minutes and tissues were then
flushed three times with PBS for 2 minutes. At room
temperature, samples were non-specifically blocked with
normal goat serum for 20 minutes. After removal of the
goat serum, rabbit anti-Bax, Bcl-2 antibody was added (in-
cubated for 60 minutes at 37°C). Biotinylated goat anti-
rabbit antibody immunoglobulin G was applied for 20 -
minutes and flushed with PBS for 2 minutes (three times).
The tissues were placed in a streptavidin-biotin-enzyme
complex reagent and incubated for 20 minutes at 37°C.
After flushing with PBS for 5 minutes (four times), samples
were stained with diaminobenzidine for 25 minutes and
washed for 3 minutes. Then samples were stained with
hematoxylin, and were dehydrated and mounted for
microscopic examination. Images of the sections were ob-
tained (400 X) using the Image-Pro plus 4.5 software
(Media Cybernetics, Silver. Spring, USA) with brown cyto-
plasmic staining under light microscopy indicating a posi-
tive reaction of Bax, Bcl-2. The myocardial infarction
border zone was chosen using a 10 high power fields
(400×), in which the mean number of bax and bcl-2 posi-
tive cells were obtained, the Bax:Bcl-2 ratio was also con-
firmed. Image Pro Plus was used for image analysis and
IOD/area was used for semi-quantity analysis.
Bcl-2 and Bax mRNA determination
① The extraction of total RNA in rat myocardium was
performed strictly following the instruction of TRNzol
RNA Reagent Kit (TIANGEN, Beijing, China). ② RNA
reverse transcription into cDNA was performed follow-
ing the instructions of the Invitrogen M-MLV cDNA kit.
Table 2 The effect of escitalopram on myocardial cells
apoptosis in rats with depression during myocardium
ischemia/reperfusion (mean ± SEM, %)
Group n Myocardial cell apoptosis index
D 8 3.08 ± 0.32
DI/R 8 37.14 ± 4.10*
Escitalopram + DI/R 8 28.87 ± 3.91*
▲
Note: *P < .01 vs D group; ▲P < .01vs DI/R group.
D group: depression group, DI/R group: depression with myocardium ischemia/
reperfusion, escitalopram + DI/R group: escitalopram + depression with
myocardium ischemia/reperfusion.
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tion assay. 5 μL DNA MarkerIwas used as the control
and 1.5% agarose gel electrophoresis was performed on
5 μL Rt-PCR product.
Statistical analysis
SPSS19.0 software was used for statistical analysis. The
results were described using (mean ± SEM). One-way
ANOVA was carried out on the basis of homogeneity of
variance, multiple comparison between the groups was
performed using S-N-K method, and P < .05 was regarded
as statistically significant.
Results
Behavioral analysis
Compared with the D and DI/R groups, rats in Escitalo-
pram +DI/R group showed significantly increased scores of
both horizontal (P < .01) and vertical movement (P < .05).
Total sucrose consumption was also significantly increased
(P < .01) (Table 1).
Infarct size
The myocardial infarct risk area of the left ventricular
area was 60 ± 2.5% (mean ± SEM) indicated by Evan Blue
staining. The size of the myocardial infarct in the myocar-
dial infarct risk area was different in three groups: (D group
0 ± 0%, DI/R group 40.28 ± 6.71%; esctialopram+DI/R group
26.35 ± 3.07%). Compared with the D group, myocardial in-
farct size in the DI/R and esctialopram +DI/R groups were
significantly increased (P < .01). Compared with the DI/R
group, myocardial infarct size in the escitalopram+DI/R
group was significantly decreased (P < .01).
The effect of escitalopram on myocardial cell apoptosis in
depression during myocardial ischemia/reperfusion
Compared with the D group, the index of myocardial
cell apoptosis in rats in the DI/R and esctialopram +DI/R
groups were significantly increased (P < .01); Compared
with the DI/R group, the index of myocardial cell apop-
tosis in the escitalopram +DI/R group was significantly
decreased(P < .01) (Table 2).Table 1 The comparison of the Open- Field test scores
and sucrose consumption of rats in different after
experiment (mean ± SEM)
Group Horizontal
movement
(scores)
Vertical
movement
(scores)
Sucrose
consumption (g)
D 53.18 ± 4.20 22.83 ± 2.34 32.25 ± 3.01
DI/R 51.57 ± 5.96 21.06 ± 2.62 30.34 ± 4.15
Escitalopram + DI/R 63.69 ± 6.11
▲ 27.51 ± 3.09* 38.73 ± 3.22▲
Note: compared with D, DI/R groups, ▲P < 0.01, *P < 0.05.
D group: depression group, DI/R group: depression with myocardium ischemia/
reperfusion, escitalopram + DI/R group: escitalopram + depression with
myocardium ischemia/reperfusion.The effect of escitalopram on Bax and Bcl-2 mRNA and
protein expression and ratio of Bax/Bcl-2 in myocardial
cell in depression during myocardial ischemia/reperfusion
Compared with the D group, in the DI/R group both Bax
and Bcl-2 mRNA and protein expression were significantly
increased (P < .01), however the ratio of Bax/Bcl-2 in the
DI/R group and the escitalopram +DI/R group was signifi-
cantly decreased (P < .01). Compared with the DI/R group,
in the escitalopram +DI/R group Bax mRNA and protein
expression was significantly decreased, while Bcl-2 mRNA
and protein expression was significantly increased, and the
ratio of Bax/Bcl-2 in escitalopram +DI/R group was signifi-
cantly decreased (P < .01) (Tables 3 and 4, Figure 1).
Discussion
The effect of escitalopram on behaviour in depression
during myocardial ischemia/reperfusion
In this study, we demonstrated that escitalopram im-
proved the behavioral phenotype and anhedonic-like state
in depression during myocardial ischemia/reperfusion,
characterized by increased scores of horizontal movements,
vertical movements and increased consumption of sucrose
solution.
The effect of myocardium ischemia/reperfusion on
myocardial cell apoptosis, Bax and Bcl-2 expression in
rats with depression
Since myocardial cells are non-renewable cells, myocardial
cell apoptosis plays an important role in myocardialTable 3 The effect of escitalopram on expression of
mRNA Bax and Bcl-2 in myocardial cells in rats with
depression during myocardium ischemia/reperfusion
(mean ± SEM, copies/g RNA)
Group Bax Bcl-2 Bax/Bcl-2
D 0.274 ± 0.0294 0.109 ± 0.0101 2.68 ± 0.14
DI/R 0.443 ± 0.0282* 0.398 ± 0.0216* 1.23 ± 0.25*
Escitalopram + DI/R 0.317 ± 0.0291
▲ 0.576 ± 0.0317▲ 0.56 ± 0.28▲
Note: *P < .01 vs D group; ▲P < .01vs DI/R group.
D group: depression group, DI/R group: depression with myocardium ischemia/
reperfusion), escitalopram + DI/R group: escitalopram + depression with
myocardium ischemia/reperfusion.
Figure 1 The expression of protein Bax and Bcl-2 in myocardial
cells (×400). A Bax in depression group, B Bax in myocardium
ischemia/reperfusion, C in escitalopram+depression with myocardium
ischemia/reperfusion group, D Bcl-2 in depression group, E Bcl-2 in
myocardium ischemia/reperfusion group, F: Bcl-2 in escitalopram +
depression with myocardium ischemia/reperfusion group.
Table 4 The effect of escitalopram on expression of
protein Bax and Bcl-2 in myocardial cells in rats with
depression during myocardium ischemia/reperfusion
(mean ± SEM, IOD)
Group Bax Bcl-2 Bax/ Bcl-2
D 5.37 ± 0.42 2.17 ± 0.29 2.55 ± 0.21
DI/R 9.45 ± 0.76* 4.97 ± 0.74* 2.06 ± 0.22*
Escitalopram + DI/R 6.62 ± 0.38
▲ 6.18 ± 0.56▲ 1.05 ± 0.18▲
Note: *P < .01 vs D group; ▲P < .01vs DI/R group.
D group: depression group, DI/R group: depression with myocardium ischemia/
reperfusion), escitalopram + DI/R group: escitalopram + depression with
myocardium ischemia/reperfusion.
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tent when the heart is in a pathological situation, such as
overload or myocardial ischemia [17]. Currently, percutan-
eous coronary intervention has become a main treatment
for clinical coronary diseases, and plays a substantive role
in revascularization strategies. But research has shown [18]
that a sudden drop in blood pressure, cardiac insufficiency,
arrhythmia, even sudden death can occur after percutan-
eous coronary intervention potentially, related to myocar-
dial ischemia-reperfusion injury (MIRI). In MIRI, anoxic
tissue injury occurs not just in acute ischemia, but after re-
storing blood perfusion. Myocardial cell apoptosis was con-
sidered one of the important factors in the pathogenesis of
ischemia-reperfusion induced injury. The scale of apoptosis
affects the gravity of MIRI.
The impact on the prognosis of coronary heart disease
complicated by depressive disorder has attracted recent
scholarly attention. Research has shown [19-21] that the
incident rate of cardiovascular events increased signifi-
cantly when coronary heart disease was complicated by
comorbid depression. Wann [22] found depression in 15-
30% of patients after myocardial infarction. Depression in-
fluences the onset, development and prognosis of coronary
heart disease. Sertraline can prevent behavioural and bio-
chemical markers in a rat model of following MI. Escitalo-
pram can modify the behavioral syndrome through
decreased pro-inflammatory cytokines and PGE2 in a rat
model of post-cardiac infarct depression [23]; however the
effects of antidepressants in this situation have not been
well explored. This study showed that compared with
depression group, the myocardial cell apoptosis index
increased significantly in rats in the depression with
myocardial ischemia/reperfusion group, suggesting that
myocardial ischemia/reperfusion might cause increased
myocardial cell apoptosis in rats with a depression
phenotype. It is probable that in the case of patient suf-
fering from AMI complicated by depression, the revas-
cularization during percutaneous coronary intervention
may result in myocardial cell apoptosis, potentially ad-
versely impact cardiac function.The mechanism whereby myocardial ischemia/reper-
fusion increases myocardial cell apoptosis in rats with
depression remains unclear. Apoptosis is a type of
genetically-regulated programmed cell death where
apoptosis-related genes play key roles, probably includ-
ing in chronic responsive stress-induced rat depression.
The Bcl-2 gene family [24-26] is considered the most
important apoptosis-inhibiting genes, and include Bcl-2
and Bax. Their genetic products are mainly located on the
mitochondrial membrane, karyotheca, and endoplasmic
reticulum. Bcl-2 inhibits apoptosis while Bax stimulates it.
This study showed that compared with the depression
group, both Bax protein and mRNA expression increased
significantly in myocardial cells in depression with myo-
cardial ischemia/reperfusion, suggesting that myocardial
ischemia/reperfusion stimulated myocardial cell apoptosis
by upregulating Bax protein expression in myocardial cells
of rats with depression. But this study also found that both
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nificantly higher in myocardial cells in rats with depres-
sion and myocardial ischemia than in the depression
group, suggesting the apoptosis-inhibiting Bcl-2 gene was
also involved in the process of ischemia/reperfusion indu-
cing myocardial cell apoptosis in rats.
Bcl-2 is expressed through forming the Bcl-2 hom-
ology 1 and 2 (BH1 and BH2) domains by binding to
Bax. When Bax expression is high, homodimer Bax/Bcl
is formed to stimulate apoptosis, and when Bcl-2 expres-
sion is high, heterodimer Bcl-2/Bax is formed to inhibit
the occurrence of apoptosis [27,28]. The regulatory ef-
fects of Bcl-2 and Bax on apoptosis is influenced not
only by their expression respectively but also by the Bcl-
2/Bax ratio. This study showed that in the depression with
myocardial ischemia/reperfusion group, Bcl-2 expression
increased significantly with an increase of Bax expression,
his also might be caused by ischemia/reperfusion stimulat-
ing Bax expression and decreasing the formation of heter
Bcl-2/Bax. This assumption still awaits further proof.
Ischemia/reperfusion induced myocardial cell apoptosis
and Bax, Bcl-2 expression in rats with depression
The role of antidepressant treatment in depression co-
morbid with CVD remains an unanswered question. In
particular, the pathophysiological processes are unclear.
5-Hydroxytryptamine (5-HT) increases heart rate and
atrial contraction through 5-HT4 receptors [29]. 5HT4
(a) and 5-HT4 (b) receptors are both expressed in the
human atrium and ventricle. SSRIs influence heart func-
tion through decreasing heart rate and ameliorating left
ventricular filling [30]. Escitalopram oxalate is the L-
antimer of citalopram, a highly selective 5-HT reuptake
inhibitor, whose inhibiting effect on 5-HT reuptake is
twice that of racemic citalopram, and 100 times that of its
d-isomer. It has low activity in inhibiting adrenalin and
dopamine receptors. In the REMIT trial [31] escitalopram
oxalate improved mental stress-induced myocardial ische-
mia defined as development of left ventricular ejection
fraction reduction, regional wall motion abnormality and/
or horizontal or down-sloping ST-segment depression, but
the mechanisms remained unclear.
This study showed that the apoptosis index of myocar-
dial cells decreased significantly in the escitalopram + is-
chemia/reperfusion group compared to the depression
with myocardium ischemia/reperfusion group, suggesting
that escitalopram might significantly decrease ischemia
and reperfusion-induced apoptosis of myocardial cells in
rats with a depression phenotype. This raises the question
as to whether escitalopram oxalate may clinically improve
heart function among patients with depression compli-
cated with AMI, particularly after percutaneous coronary
intervention. Furthermore, this study showed that com-
pared with the ischemia/reperfusion group, Bax mRNAand protein expression decreased significantly, while Bcl-2
mRNA and protein expression increased significantly,
moreover the Bax/Bcl-2 ratio decreased significantly, sug-
gesting escitalopram may decrease ischemia/reperfusion
induced apoptosis of myocardial cells in rats with a de-
pression phenotype by upregulating Bcl-2 expression and
down-regulating Bax expression.
This study has certain limitations that need to be kept in
mind when interpreting these data. In this study, a control
group of IR rats without pre-MI depression was lack. In
our previous study (4), a control group of none-depressed
animals with myocardial infarction (MI) was examined.
We found that there were no behavioural signs of depres-
sion compared with depression group. Moreover in the
post-MI depression group, there was a greater up-
regulated Bax:Bcl-2 ratio compared with the MI group.
The results of this animal model suggest that active
pro-apoptotic pathways may be involved in the nexus
between myocardial infarction and depression. In the
current study, our aim was to explore the molecular
mechanisms of escitalopram on myocardial apoptosis in a
rat model of depression during myocardial ischemia/re-
perfusion (I/R), all rats were therefore deemed depressive
rats, so we think that IR rats group without pre-MI de-
pression is not necessary in this study, but this does re-
quire caution in the interpretation of the animal findings.
Conclusions
These results suggest that in patients with myocardial in-
farction comorbid with major depressive disorder, there
may be an increase in pro-apoptotic pathways that is poten-
tially reversed by escitalopram. This suggests that escitalo-
pram oxalate may have the potential to clinically improve
heart function after patients with depression complicated
with acute myocardial infarction after the percutaneous
coronary intervention.
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